Exploratory Machine Learning Studies for Disruption Prediction Using Large Databases on DIII-D: Fusion Science and Technology: Vol 74, No 1-2
![Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial - Annals of Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial - Annals of](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/cd5366ee-f059-4c08-9a16-c4b257fd0f80/gr2_lrg.jpg)
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial - Annals of
![Meta-Analysis of Therapeutic Procedures for Acquired Subglottic Stenosis in Adults - The Annals of Thoracic Surgery Meta-Analysis of Therapeutic Procedures for Acquired Subglottic Stenosis in Adults - The Annals of Thoracic Surgery](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/62316df8-71a2-4f5c-a875-3173d9d49076/gr1.jpg)
Meta-Analysis of Therapeutic Procedures for Acquired Subglottic Stenosis in Adults - The Annals of Thoracic Surgery
![Small Extracellular Vesicles from adipose derived stromal cells significantly attenuate in vitro the NF-κB dependent inflammatory/catabolic environment of osteoarthritis | Scientific Reports Small Extracellular Vesicles from adipose derived stromal cells significantly attenuate in vitro the NF-κB dependent inflammatory/catabolic environment of osteoarthritis | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-020-80032-7/MediaObjects/41598_2020_80032_Fig1_HTML.png)
Small Extracellular Vesicles from adipose derived stromal cells significantly attenuate in vitro the NF-κB dependent inflammatory/catabolic environment of osteoarthritis | Scientific Reports
![Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study | Leukemia Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2012.181/MediaObjects/41375_2013_Article_BFleu2012181_Fig1_HTML.jpg)